Xact Kapitalforvaltning AB trimmed its position in Nektar Therapeutics (NASDAQ:NKTR) by 4.8% in the 1st quarter, HoldingsChannel.com reports. The firm owned 31,510 shares of the biopharmaceutical company’s stock after selling 1,581 shares during the quarter. Xact Kapitalforvaltning AB’s holdings in Nektar Therapeutics were worth $1,059,000 at the end of the most recent reporting period.
A number of other large investors have also recently made changes to their positions in NKTR. Meeder Asset Management Inc. lifted its holdings in shares of Nektar Therapeutics by 150.2% during the 1st quarter. Meeder Asset Management Inc. now owns 798 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 479 shares during the last quarter. Quantamental Technologies LLC bought a new stake in shares of Nektar Therapeutics during the 1st quarter worth $27,000. CSat Investment Advisory L.P. lifted its holdings in shares of Nektar Therapeutics by 279.2% during the 4th quarter. CSat Investment Advisory L.P. now owns 1,073 shares of the biopharmaceutical company’s stock worth $35,000 after acquiring an additional 790 shares during the last quarter. Laurel Wealth Advisors LLC bought a new stake in shares of Nektar Therapeutics during the 4th quarter worth $39,000. Finally, Sandy Spring Bank bought a new stake in shares of Nektar Therapeutics during the 4th quarter worth $59,000. 92.28% of the stock is owned by hedge funds and other institutional investors.
In related news, COO John Nicholson sold 4,077 shares of the business’s stock in a transaction dated Thursday, May 16th. The shares were sold at an average price of $31.37, for a total transaction of $127,895.49. Following the transaction, the chief operating officer now owns 166,578 shares in the company, valued at $5,225,551.86. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, SVP Stephen K. Doberstein sold 3,461 shares of the business’s stock in a transaction dated Thursday, May 16th. The shares were sold at an average price of $31.37, for a total transaction of $108,571.57. Following the transaction, the senior vice president now owns 95,913 shares in the company, valued at approximately $3,008,790.81. The disclosure for this sale can be found here. Insiders sold 159,949 shares of company stock worth $5,232,600 in the last 90 days. Corporate insiders own 4.31% of the company’s stock.
Nektar Therapeutics stock traded up $0.18 during mid-day trading on Wednesday, hitting $33.45. The company’s stock had a trading volume of 40,907 shares, compared to its average volume of 1,738,582. The company has a quick ratio of 14.83, a current ratio of 14.94 and a debt-to-equity ratio of 0.21. The company has a market capitalization of $5.80 billion, a PE ratio of 8.81 and a beta of 2.80. Nektar Therapeutics has a 12 month low of $29.22 and a 12 month high of $69.76.
Nektar Therapeutics (NASDAQ:NKTR) last posted its quarterly earnings results on Wednesday, May 8th. The biopharmaceutical company reported ($0.68) earnings per share for the quarter, topping the consensus estimate of ($0.71) by $0.03. Nektar Therapeutics had a net margin of 55.65% and a return on equity of 37.63%. The business had revenue of $28.22 million during the quarter, compared to the consensus estimate of $25.45 million. During the same period in the previous year, the firm posted ($0.60) earnings per share. As a group, equities analysts expect that Nektar Therapeutics will post -3.14 earnings per share for the current fiscal year.
A number of analysts have recently issued reports on the stock. BidaskClub downgraded shares of Nektar Therapeutics from a “sell” rating to a “strong sell” rating in a report on Wednesday. William Blair reaffirmed a “buy” rating on shares of Nektar Therapeutics in a report on Tuesday, June 4th. ValuEngine raised shares of Nektar Therapeutics from a “hold” rating to a “buy” rating in a research note on Monday, June 3rd. Cowen set a $82.00 price target on shares of Nektar Therapeutics and gave the stock a “buy” rating in a research note on Sunday, June 2nd. Finally, Mizuho reissued a “buy” rating and issued a $81.00 price target on shares of Nektar Therapeutics in a research note on Friday, May 24th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and nine have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $68.50.
TRADEMARK VIOLATION NOTICE: This report was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this report on another website, it was copied illegally and reposted in violation of U.S. and international copyright and trademark law. The original version of this report can be read at https://www.dispatchtribunal.com/2019/06/12/xact-kapitalforvaltning-ab-has-1-06-million-holdings-in-nektar-therapeutics-nasdaqnktr.html.
Nektar Therapeutics Company Profile
Nektar Therapeutics, a biopharmaceutical company, develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States. The company develops NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; and NKTR-214, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in Phase I to treat immuno-oncology.
Further Reading: What is a Call Option?
Want to see what other hedge funds are holding NKTR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Nektar Therapeutics (NASDAQ:NKTR).
Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.